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complication, 2.8% due to a long-term diabetes complication and 1.9% due to 
uncontrolled diabetes. In logistic regression adjusting for age, sex, race and comorbidi-
ties, nonadherence to all three classes of medications (OR  1.49, 95% CI:1.44–1.55), 
adherence to any 1 class of medications (OR  1.41, 95% CI:1.36–1.47), adherence 
to any 2 classes of medications (OR  1.26, 95% CI:1.21–1.30) were associated with 
higher risks for PAHs compared to adherence with all three classes of medications. 
CONCLUSIONS: Medication adherence is necessary to reduce the risk of PAHs. 
Interventions are needed to improve medication adherence, which will help patients 
realize the full beneﬁ t of hypoglycemic and cardioprotective medications.
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OBJECTIVES: To examine the association between nonadherence to oral hypoglyce-
mics and potentially avoidable hospitalizations due to diabetes short-term complica-
tions among Medicare Part D enrollees. METHODS: This is a longitudinal retrospective 
cohort study. Medicare Part D enrollees with diabetes from six states (Alabama, Cali-
fornia, Florida, Mississippi, New York, and Ohio) who had ﬁ lled at least 1 prescription
for oral hypoglycemics during the ﬁ rst half of 2006 were included in the study. Medi-
care Part D claims data for the ﬁ rst 6 months of 2006 were evaluated for adherence
with oral hypoglycemics using proportion of days covered (PDC). Patients were clas-
siﬁ ed as adherent (PDC q 0.8), poor adherent (0.5 a PDC  0.8), and very poor
adherent (0  PDC  0.5). Patients’ Part A records from July 1, 2006 to March 31,
2007 were evaluated for potentially avoidable hospitalizations due to diabetes short-
term complications, one of the diabetes care prevention quality indicators recom-
mended by the Agency for Healthcare Research and Quality. Associations between 
nonadherence and outcomes were assessed using multivariate regression models. 
RESULTS: Data were available for 1,101,533 patients. Among them, 58.4% were
females and the mean age was 71.7 years. About 64.9% were adherent, 11.2% 
were poor adherent, and 24.0% were very poor adherent with oral hypoglycemics. 
Of all patients, 1540 had at least one hospital admissions due to diabetes short-
term complications during the outcome measurement period. After controlling for 
age, gender, race, and comorbidities (Charlson Comorbidity Index), the odds for hos-
pital admission due to diabetes short-term complications was 25.4% (OR: 1.254; 
95%CI: 1.072–1.467) higher for poor adherent patients and 48.0% (OR: 1.480; 
95%CI: 1.326–1.653) higher for very poor adherent patients when compared to 
patients who were adherent to oral hypoglycemics. CONCLUSIONS: Nonadherence 
to oral hypoglycemics is associated with increased risks for potentially avoidable hos-
pitalizations due to diabetes short-term complications. Medicare prescription drug
plans should consider developing targeted interventions to improve adherence to oral
hypoglycemics.
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OBJECTIVES: There is a scarcity of the literature evaluating the impact of Medicaid
payment mechanisms on outcomes in diabetes. The objectives of this study was to
examine the impact of Capitated vs. Fee-For-Service (FFS) health plans on medication
adherence and health care service utilizations in type-2 diabetes Medicaid enrollees.
METHODS: A retrospective database study comprised of patients with type-2 diabe-
tes (n  8,581) enrolled in the Medstat MarketScan MultiState Medicaid database
from July 1, 2002 to December 31, 2005. Patients were followed for 6 months before 
and 12 months after the index anti-diabetic medication to collect the data on the
baseline characteristics, medication adherence and health care service utilizations.
Multiple log-linear regression analysis was used to predict medication adherence and
logistic regressions were used to examine the health care service utilizations. RESULTS:
A total of 3763 (44%) of the patients enrolled in capitated plans and 4818 (56%) in 
FFS plans. Patients with capitated plans had 5% lower adherence to anti-diabetes
medications compared to those with FFS plans (5%; P  0.05). Patients with capitated 
health plans had 33% more likelihood of getting hospitalized (OR: 1.33; 95% CI: 
1.17, 1.49) and 16% increased odds of having ER visit as compared to those with 
FFS (OR: 1.16; 95% CI: 1.06, 1.28). Further, 10% increase in medication adherence 
was associated with 7% decreased in the odds of hospitalizations (OR: 0.53; 95%CI:
0.46, 0.66) and 6% decreased in the odds of ER visits (OR: 0.48; 95% CI: 0.40, 0.55).
CONCLUSIONS: Patients with capitated health plans had signiﬁ cant lower medica-
tion adherence and also associated with signiﬁ cantly higher health care service utiliza-
tions. Capitated managed care plans may not be cost effective for the long term
management of chronic conditions such as diabetes.
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OBJECTIVES: Access to prescription drugs may be controlled by formulary step edits. 
Speciﬁ c criteria are sometimes set by insurers for drug coverage. Exenatide coverage
may require previous prescriptions for oral antidiabetics (OAD), typically either met-
formin (MET), sulfonylureas (SULF) or thiazolidediones (TZD) within speciﬁ c inter-
vals or “look-back windows”. These typically range from 60 to 180 days. This analysis
assessed the timing of OAD claims prior to initiation of exenatide. METHODS: Data 
were obtained from the HealthCore Integrated Research DatabaseTM. Adult patients
had a claim for exenatide between May 1, 2005 and March 31, 2008, q12 months 
pre-index eligibility, and a type-2 diabetes diagnosis (N  22,533). RESULTS: A pre-
index OAD claim was present for 20,228 (95%) patients. The mean (oSD) duration 
for any previous claim of either MET, SULF or TZD was 60 o 116. For MET, SULF
and TZD individually, durations were 95 o 168, 116 o 202, and 135 o 200 days,
respectively. For patients q65 years (n  2301) the mean (oSD) duration for any previ-
ous claim for either MET, SULF or TZD was 63 o 114 days and for MET, SULF and 
TZD individually, durations were 110 o 174, 104 o 169, and 144 o 199 days, respec-
tively. Of the entire cohort 6280 (28%) did not have a claim for MET, SULF or TZD
within 60 days of exenatide. Of those with an OAD claim, 3975 (20%) did not have
a claim for MET, SULF or TZD within 60 days. CONCLUSIONS: These data repre-
sent only successfully adjudicated exenatide claims. Plans in this database may have 
had OAD step edits in place at some time during the study period. For plans with no
OAD step edits, mean durations may have been longer and the percent of patients 
with ﬁ lls after 60 days higher. This analysis supports careful consideration of look-
back window durations. Overly restrictive intervals (i.e., 60 days) may inappropriately
exclude patients from receiving exenatide.
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OBJECTIVES: To provide the optimal beneﬁ t-risk proﬁ le, OADs must be appropri-
ately titrated and, often, used in combination. We compared overall health care utiliza-
tion and costs among diabetic patients who added a new OAD medication to initial 
therapy and those with up-titration of initial OAD METHODS: Insurance claims data 
were obtained from ~90 health plans for patients age q18 years with diagnosis of 
T2DM based on q2 ICD-9 claims during the period January 1, 2001–June 30, 2007
and newly prescribed metformin or sulfonylurea monotherapy regimen lasting q90 
days. Patients with type-1 or gestational diabetes, or OAD use within 180 days prior,
were excluded. Patients (N  22,917) were followed after initiation of monotherapy
to identify occurrence of ﬁ rst treatment modiﬁ cation (addition or up-titration). Study 
outcomes were analyzed during one year after ﬁ rst treatment modiﬁ cation. RESULTS:
Overall, 27% of patients (n  6,191) had a new OAD added to their initial OAD, 
while 73% of patients (n  16,726) had initial OAD up-titrated. During the post-
treatment modiﬁ cation period, all medication costs for the addition cohort were higher 
than for the up-titration cohort [mean (SD), median  $4618.67 ($8313.00), $2870.73 
vs. $4004.19 ($8158.37), $2188.345; p  0.0001] but total health care costs were 
lower [$8157.41 (16771.09), $4264.44 vs. $8447.33 (20281.44), $4764.17; p 
0.0001], largely due to lower costs for inpatient admissions [$1641.76 ($10124.90), 
$1647.73 vs. $1960.42 ($13363.90), $1819.10; p  0.0002]. In a multivariable model
adjusting for prior health care expenditure, demographic and clinical variables, total 
costs of new OAD addition remained signiﬁ cantly lower than costs of initial OAD 
up-titration [$9568 vs. $10027.13; p  0.048]. CONCLUSIONS: Up-titration of 
initial OAD therapy was associated with higher subsequent total health care costs 
than addition of another OAD, perhaps due to limited incremental efﬁ cacy when up-
titrating beyond intermediate doses. When appropriate, physicians should consider
adding an OAD rather than up-titrating the current OAD.
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OBJECTIVES: To evaluate the effect of pharmacist interventions on diabetic patient
outcomes compared to usual care without pharmacist clinical intervention. 
METHODS: The study was implemented in “Safety Net” clinics located in Los 
Angeles County serving poor, Hispanic patients. Pharmacist services included review 
of the patient’s medical and medication history, medication evaluation and adjust-
ments or deletions under an established protocol, ordering and reviewing routine labo-
ratory tests [e.g., HbA1c levels, LDL, HDL, etc.], monitoring patient compliance, 
patient education and scheduling follow-up visits. Control patients were selected ret-
rospectively to match the intervention cohort. The primary outcome was measured as 
the reduction of A1c and the percentage of patients who achieved the treatment goal, 
an A1c 7%. Secondary outcomes focused on the diabetes-related outcomes, a
decreased in blood pressure, lipid levels and BMI. METHODS:: Multiple linear regres-
